{
  "schema_version": "1.0",
  "type": "article",
  "title": "Hanmi's Half-Price Obesity Shot Takes On Mounjaro. Wegovy Feels It First",
  "url": "https://drugnews.com.tw/articles/2026-10-20-korea-glp1-price-war-hanmi-eppe-novo-en.html",
  "markdown_url": "https://drugnews.com.tw/articles/2026-10-20-korea-glp1-price-war-hanmi-eppe-novo-en.md",
  "lang": "en",
  "date": "2026-10-20",
  "publish_at": "2026-10-20T08:00:00+08:00",
  "updated_at": "2026-10-20",
  "category": "商業分析系列",
  "topic": "商業分析系列",
  "tags": [
    "Hanmi",
    "Eppe",
    "Mounjaro",
    "Wegovy",
    "obesity drugs"
  ],
  "summary": "Oct 7, Seoul: Hanmi's homegrown obesity shot Eppe is approved at about half Mounjaro's starter price. Six days later, Novo seeks insurance for Wegovy. Mounjaro keeps its 90%; Wegovy feels it first.",
  "key_points": [
    "Hanmi Pharmaceutical's homegrown GLP-1 obesity shot Eppe (efpeglenatide) was approved in Korea on October 7, 2026; an industry quote on October 14 put its first month at 129,800 won, about half of Mounjaro 2.5 mg at roughly 270,000 won for four weeks.",
    "In June 2026 Mounjaro held 86.7% of Korea's GLP-1 weight-loss market and Wegovy 13.2%; on October 13, 2026, Novo Nordisk was reported to have applied to Korea's HIRA for national insurance coverage of Wegovy.",
    "At its 10 mg maintenance dose in month four, Eppe costs 299,200 won a month, only 17% below Wegovy and 19% below Mounjaro; with 9.75% weight loss at Week 40, it competes in Wegovy's efficacy tier, so the price pressure lands on Wegovy first."
  ],
  "facts": [
    {
      "claim": "Mounjaro share of Korea's GLP-1 weight-loss market (June 2026, BRP Insight)",
      "value": 86.7,
      "unit": "%",
      "as_of": "2026-06-30",
      "source": "https://www.koreaherald.com/article/10901056"
    },
    {
      "claim": "Wegovy share of Korea's GLP-1 weight-loss market (June 2026, BRP Insight)",
      "value": 13.2,
      "unit": "%",
      "as_of": "2026-06-30",
      "source": "https://www.koreaherald.com/article/10901056"
    },
    {
      "claim": "Mounjaro 2.5 mg lowest four-week price in Korea",
      "value": 270000,
      "unit": "won",
      "as_of": "2026-10-13",
      "source": "https://www.koreaherald.com/article/10901056"
    },
    {
      "claim": "Wegovy 0.25 mg lowest price in Korea",
      "value": 210000,
      "unit": "won",
      "as_of": "2026-10-13",
      "source": "https://www.koreaherald.com/article/10901056"
    },
    {
      "claim": "Eppe first-month price (2 mg and 4 mg, industry quote, incl. VAT)",
      "value": 129800,
      "unit": "won",
      "as_of": "2026-10-14",
      "source": "https://en.sedaily.com/finance/2026/10/14/hanmis-efpe-obesity-drug-to-cost-129800-won-in-first-month"
    },
    {
      "claim": "Eppe fourth-month price (10 mg, industry quote, incl. VAT)",
      "value": 299200,
      "unit": "won",
      "as_of": "2026-10-14",
      "source": "https://en.sedaily.com/finance/2026/10/14/hanmis-efpe-obesity-drug-to-cost-129800-won-in-first-month"
    },
    {
      "claim": "Eppe starter-dose discount vs Mounjaro",
      "value": 53,
      "unit": "%",
      "as_of": "2026-10-14",
      "source": "https://en.sedaily.com/finance/2026/10/14/hanmis-efpe-obesity-drug-to-cost-129800-won-in-first-month"
    },
    {
      "claim": "Eppe maintenance-dose discount vs Wegovy",
      "value": 17,
      "unit": "%",
      "as_of": "2026-10-14",
      "source": "https://en.sedaily.com/finance/2026/10/14/hanmis-efpe-obesity-drug-to-cost-129800-won-in-first-month"
    },
    {
      "claim": "Eppe maintenance-dose discount vs Mounjaro",
      "value": 19,
      "unit": "%",
      "as_of": "2026-10-14",
      "source": "https://en.sedaily.com/finance/2026/10/14/hanmis-efpe-obesity-drug-to-cost-129800-won-in-first-month"
    },
    {
      "claim": "Hanmi annual sales target for Eppe",
      "value": 100,
      "unit": "billion won or more",
      "as_of": "2026-10-14",
      "source": "https://en.sedaily.com/finance/2026/10/14/hanmis-efpe-obesity-drug-to-cost-129800-won-in-first-month"
    },
    {
      "claim": "Eppe Phase 3 mean body-weight change at Week 40 (placebo -0.95%, 448 Korean adults)",
      "value": -9.75,
      "unit": "%",
      "as_of": "2025-10-27",
      "source": "https://www.hanmipharm.com/about/investor-relations/press/detail-3763.hm"
    },
    {
      "claim": "Eppe Phase 3 share of patients losing at least 10% at Week 40",
      "value": 49.46,
      "unit": "%",
      "as_of": "2025-10-27",
      "source": "https://www.hanmipharm.com/about/investor-relations/press/detail-3763.hm"
    },
    {
      "claim": "Mounjaro prescriptions in Korea, June 2026 (HIRA DUR)",
      "value": 335306,
      "unit": "prescriptions",
      "as_of": "2026-07-30",
      "source": "https://en.sedaily.com/culture/2026/07/30/wegovy-falls-20-fold-behind-mounjaro-in-new-prescriptions"
    },
    {
      "claim": "Wegovy monthly prescription peak in Korea (May 2025)",
      "value": 88895,
      "unit": "prescriptions",
      "as_of": "2026-07-30",
      "source": "https://en.sedaily.com/culture/2026/07/30/wegovy-falls-20-fold-behind-mounjaro-in-new-prescriptions"
    },
    {
      "claim": "Mounjaro starter-dose prescriptions vs Wegovy starter dose (June 2026)",
      "value": 19.6,
      "unit": "times",
      "as_of": "2026-07-30",
      "source": "https://en.sedaily.com/culture/2026/07/30/wegovy-falls-20-fold-behind-mounjaro-in-new-prescriptions"
    },
    {
      "claim": "Wegovy lowest-dose price cut before Mounjaro launch",
      "value": 42,
      "unit": "%",
      "as_of": "2026-07-30",
      "source": "https://en.sedaily.com/culture/2026/07/30/wegovy-falls-20-fold-behind-mounjaro-in-new-prescriptions"
    },
    {
      "claim": "Eppe approved in Korea as the 45th homegrown new drug",
      "value": "2026-10-07",
      "unit": "date",
      "as_of": "2026-10-07",
      "source": "https://www.koreatimes.co.kr/business/companies/20261016/koreas-1st-homegrown-obesity-drug-likely-to-intensify-price-competition"
    },
    {
      "claim": "Eppe Phase 3 nausea rate",
      "value": 16.6,
      "unit": "%",
      "as_of": "2026-10-08",
      "source": "https://www.koreajoongangdaily.com/business/koreas-first-glp1-obesity-drug-wins-approval-with-less-weight-loss-but-fewer-side-effects/12910491"
    },
    {
      "claim": "Sanofi notified Hanmi it would return all efpeglenatide rights",
      "value": "2020-05-14",
      "unit": "date",
      "as_of": "2020-05-14",
      "source": "https://www.koreabiomed.com/news/articleView.html?idxno=8244"
    },
    {
      "claim": "Upfront payment Hanmi received from Sanofi for efpeglenatide",
      "value": 200,
      "unit": "million euros",
      "as_of": "2020-05-14",
      "source": "https://www.koreabiomed.com/news/articleView.html?idxno=8244"
    },
    {
      "claim": "Obesity-drug smuggling cases caught by Korea Customs, Jan–Aug 2026 (4.2x prior year)",
      "value": 5030,
      "unit": "cases",
      "as_of": "2026-10-16",
      "source": "https://www.koreatimes.co.kr/business/companies/20261016/koreas-1st-homegrown-obesity-drug-likely-to-intensify-price-competition"
    },
    {
      "claim": "Maximum Mounjaro price cut in China",
      "value": 66,
      "unit": "%",
      "as_of": "2026-10-16",
      "source": "https://www.koreatimes.co.kr/business/companies/20261016/koreas-1st-homegrown-obesity-drug-likely-to-intensify-price-competition"
    },
    {
      "claim": "Mounjaro street price in Taiwan (all doses)",
      "value": "9,500–15,000",
      "unit": "NT$",
      "as_of": "2026-01-19",
      "source": "https://www.twreporter.org/a/illicit-drug-distribution-of-glp-1-gip-in-taiwan-1"
    },
    {
      "claim": "Estimated patient out-of-pocket cost for Eppe's first month",
      "value": "140,000–200,000",
      "unit": "won",
      "as_of": "2026-10-15",
      "source": "https://www.ajupress.com/view/20261015085413145"
    },
    {
      "claim": "Exchange rate USD/KRW (USD/TWD 32.36)",
      "value": 1342.74,
      "unit": "won",
      "as_of": "2026-10-16",
      "source": "https://open.er-api.com/v6/latest/USD"
    }
  ],
  "sections": [
    "01 | Korea's obesity market has one dominant player",
    "02 | Same weekly shot, different switches",
    "03 | Lilly, Novo and Hanmi: what each one competes with",
    "04 | Half price lasts one month",
    "05 | Taiwan pays NT$9,500 and up, and is watching Korea",
    "References"
  ],
  "references": [
    {
      "title": "Wegovy seeks insurance edge in Korea's obesity drug war",
      "source": "The Korea Herald",
      "date": "2026-10-13",
      "url": "https://www.koreaherald.com/article/10901056"
    },
    {
      "title": "Hanmi's Efpe Obesity Drug to Cost 129,800 Won in First Month",
      "source": "Seoul Economic Daily",
      "date": "2026-10-14",
      "url": "https://en.sedaily.com/finance/2026/10/14/hanmis-efpe-obesity-drug-to-cost-129800-won-in-first-month"
    },
    {
      "title": "Price War Heats Up as Novo Seeks Insurance Coverage for Wegovy in Korea",
      "source": "Seoul Economic Daily",
      "date": "2026-10-16",
      "url": "https://en.sedaily.com/finance/2026/10/16/price-war-heats-up-as-novo-seeks-insurance-coverage-for"
    },
    {
      "title": "Korea's 1st homegrown obesity drug likely to intensify price competition",
      "source": "The Korea Times",
      "date": "2026-10-16",
      "url": "https://www.koreatimes.co.kr/business/companies/20261016/koreas-1st-homegrown-obesity-drug-likely-to-intensify-price-competition"
    },
    {
      "title": "Hanmi's Eppe priced at 129,800 won for first month (Hanmi spokesperson on pricing, in Korean",
      "source": "News Journalism",
      "date": "2026-10-15",
      "url": "https://www.ngetnews.com/news/articleView.html?idxno=554556"
    },
    {
      "title": "Korea's first GLP-1 obesity drug wins approval with less weight loss but fewer side effects",
      "source": "Korea JoongAng Daily",
      "date": "2026-10-08",
      "url": "https://www.koreajoongangdaily.com/business/koreas-first-glp1-obesity-drug-wins-approval-with-less-weight-loss-but-fewer-side-effects/12910491"
    },
    {
      "title": "Korea's Homegrown GLP-1 obesity therapy with Favorable Efficacy and Safety Nears Filing (Phase 3 Week 40 interim",
      "source": "Hanmi Pharmaceutical",
      "date": "2025-10-27",
      "url": "https://www.hanmipharm.com/about/investor-relations/press/detail-3763.hm"
    },
    {
      "title": "Wegovy Falls 20-Fold Behind Mounjaro in New Prescriptions, May Cut Prices Again",
      "source": "Seoul Economic Daily",
      "date": "2026-07-30",
      "url": "https://en.sedaily.com/culture/2026/07/30/wegovy-falls-20-fold-behind-mounjaro-in-new-prescriptions"
    },
    {
      "title": "Sanofi to return efpeglenatide rights to Hanmi",
      "source": "Korea Biomedical Review",
      "date": "2020-05-14",
      "url": "https://www.koreabiomed.com/news/articleView.html?idxno=8244"
    },
    {
      "title": "Hanmi files phase 3 IND for Korean-customized obesity drug efpeglenatide",
      "source": "KED Global",
      "date": "2023-07-31",
      "url": "https://www.kedglobal.com/newsView/ked202307310013"
    },
    {
      "title": "LAPSCOVERY: Long-Acting Protein/Peptide Discovery platform technology",
      "source": "LAPAL",
      "date": "2026-10-17",
      "url": "https://lapal.ch/technology/lapscovery-long-acting-protein-peptide-discovery-platform-technology"
    },
    {
      "title": "Social media sales, pharmacy back doors and Japan shoppers: Taiwan's illicit GLP-1 network (in Chinese",
      "source": "The Reporter",
      "date": "2026-01-19",
      "url": "https://www.twreporter.org/a/illicit-drug-distribution-of-glp-1-gip-in-taiwan-1"
    },
    {
      "title": "Hanmi's new obesity drug to launch this month at half Mounjaro's price",
      "source": "Aju Press",
      "date": "2026-10-15",
      "url": "https://www.ajupress.com/view/20261015085413145"
    },
    {
      "title": "USD exchange rates (TWD 32.36, KRW 1,342.74, JPY 158.09",
      "source": "ExchangeRate-API",
      "date": "2026-10-16",
      "url": "https://open.er-api.com/v6/latest/USD"
    }
  ],
  "images": [
    {
      "alt": "Fig. 1 | Three obesity shots, three ways to flip the switch",
      "url": "https://drugnews.com.tw/assets/articles/korea-glp1-price-war-hanmi-eppe-novo-en/figure-01.png"
    },
    {
      "alt": "Fig. 2 | Starter price in Korea: Eppe is about half of Mounjaro",
      "url": "https://drugnews.com.tw/assets/articles/korea-glp1-price-war-hanmi-eppe-novo-en/figure-02.png"
    },
    {
      "alt": "Fig. 3 | Eppe monthly cost: month four is 2.3x month one",
      "url": "https://drugnews.com.tw/assets/articles/korea-glp1-price-war-hanmi-eppe-novo-en/figure-03.png"
    },
    {
      "alt": "Fig. 4 | Three companies, three strategies: Lilly competes on efficacy, Novo on insurance, and Hanmi on entry price and domestic manufacturing.",
      "url": "https://drugnews.com.tw/assets/articles/korea-glp1-price-war-hanmi-eppe-novo-en/figure-04.png"
    }
  ],
  "cover_image": "https://drugnews.com.tw/assets/articles/korea-glp1-price-war-hanmi-eppe-novo-en/cover.png",
  "publisher": {
    "name": "Drugnews｜藥時事",
    "url": "https://drugnews.com.tw/",
    "profile": "https://drugnews.com.tw/brand-profile.json"
  },
  "citation": "Drugnews｜藥時事（2026-10-20）。Hanmi's Half-Price Obesity Shot Takes On Mounjaro. Wegovy Feels It First。https://drugnews.com.tw/articles/2026-10-20-korea-glp1-price-war-hanmi-eppe-novo-en.html",
  "disclaimer": "This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.",
  "translations": {}
}